Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q8N7B9
UPID:
EFCB3_HUMAN
Alternative names:
-
Alternative UPACC:
Q8N7B9; J3KQM8
Background:
EF-hand calcium-binding domain-containing protein 3, identified by the accession number Q8N7B9, plays a crucial role in calcium signaling, a pivotal process in cellular responses. This protein, through its EF-hand domain, is capable of binding calcium ions, thereby participating in a wide range of cellular functions including muscle contraction, neurotransmitter release, and gene expression.
Therapeutic significance:
Understanding the role of EF-hand calcium-binding domain-containing protein 3 could open doors to potential therapeutic strategies. Its involvement in calcium signaling pathways presents an opportunity for the development of novel treatments targeting diseases where calcium homeostasis is disrupted.